After treated with different anti-cancer agents (cisplatin, MG132, paclitaxel and SAHA), both BTG3 transfectants showed lower viability and higher apoptosis than the control in both time- and dose-dependent manners (Figure 3A-3B, p < 0.05). The gene discussed is BTG3; the disease is cancer.